Nektar Therapeutics (NKTR) Current Leases (2011 - 2026)

Nektar Therapeutics' Current Leases history runs 14 years deep, the most recent figure standing at $22.5 million for Q1 2026.

• In Q1 2026, Current Leases rose 3.15% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $22.5 million (up 3.15% YoY), while the FY2025 annual figure was $20.5 million, up 3.16% from the prior year.
• Current Leases for Q1 2026 stood at $22.5 million, up from $20.5 million in the prior quarter.
• The five-year high for Current Leases was $22.5 million in Q1 2026, with the low at $18.5 million in Q3 2022.
• The 5-year median for Current Leases is $19.9 million (2024), against an average of $20.2 million.
• The sharpest annual moves came in 2022 and 2023: Current Leases advanced 24.28% in 2022, then slipped 5.56% in 2023.
• Nektar Therapeutics' Current Leases stood at $18.7 million in 2022, then advanced by 3.17% to $19.3 million in 2023, then grew by 3.16% to $19.9 million in 2024, then advanced by 3.16% to $20.5 million in 2025, then gained by 9.93% to $22.5 million in 2026.
• Business Quant data shows NKTR's Current Leases at $22.5 million in Q1 2026, $20.5 million in Q4 2025, and $22.2 million in Q3 2025.